Research programme: phospholamban regulators - Edwards Lifesciences/Sangamo Therapeutics
Alternative Names: ZFP TF therapeutic angiogenesis programme - Sangamo; ZFP TFs for cardiovascular and vascular indications - Edwards Lifesciences/SangamoLatest Information Update: 11 Jan 2017
At a glance
- Originator Edwards Lifesciences Corporation; Sangamo BioSciences
- Class Zinc finger DNA binding proteins
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure